efferon-lps-2022-01
Проводит Efferon JSC
Страница компанииMulticenter Observational Prospective Study of the Efficacy and Safety of Selective Lipopolysaccharide Hemosorption Using the Efferon LPS Device in Maternal Sepsis Complicated by Organ Dysfunction and/or Septic Shock
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT05711901/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Исследование завершено, новых участников не набирают.
- Возраст участников: от 18 лет, только женщины. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 30 чел. во всех странах исследования.
- Центров в реестре: 7 в 6 городах. Список — ниже на странице.
- Плановая дата окончания (06.2024) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 7 · невключение: 11
Критерии включения
- Age ≥18 years
- An established diagnosis of sepsis according to the criteria for SEPSIS-3, most likely Gram-negative etiology, at the time of inclusion.
- No more than 12 hours from the time of setting DS - Sepsis and/or Septic Shock.
- In case of septic shock:
- Hypotension requiring vasopressor support for at least 2 hours continuously and no more than 12 hours.
- In the absence of Septic shock, but in the presence of suspicion of sepsis (before the detection of flora) and organ dysfunction, inclusion in the clinical trial is based on 2 of the 4 SIRS criteria,
- SOFA ≥ 4 points.
Критерии невключения
- Inability to obtain informed consent from the patient, family member or legal representative,
- The presence of a focus of non-sanitized surgical infection,
- The use of other methods of extracorporeal removal of LPS and inflammatory mediators in the treatment of septic shock (hemofilters with highly permeable and surface-modified membranes)
- In Septic Shock, failure to achieve or maintain a minimum mean arterial pressure (MAP) ≥ 65 mmHg. Art., despite vasopressor therapy and infusion therapy for 24 hours,
- End-stage renal disease and need for chronic dialysis.
- Acute pulmonary embolism
- Transfusion reaction,
- Severe congestive heart failure,
- Uncontrolled bleeding (acute blood loss in the last 24 hours),
- Severe granulocytopenia (white blood cell count less than 500 cells/mm3),
- Any other condition that, in the opinion of the investigator, would prevent the patient from being a suitable candidate for inclusion in the study (eg terminal chronic disease).
Источник: ClinicalTrials.gov, NCT05711901 · запись обновлена в реестре 2 ноября 2026.
Дизайн и результаты
Что измеряют — первичные конечные точки (2), вторичных — 3
- Effect of Efferon LPS hemoperfusion on SOFA (Sequential Organ Failure Assessment) scores in patients with obstetric sepsis. — 1-72 hours
- The effect of Efferon-LPS hemoperfusion on hemodynamic parameters in patients with obstetric sepsis — Time (number of hours) from enrollment in the study to the end of vasopressor support during 14 days of follow-up
Цель исследования
One of the major health problems in the world is sepsis, the number of cases of which, according to WHO, annually reaches 20-30 million.
The prevalence and frequency of obstetric sepsis are quite pronounced. Thus, in Europe, up to 500,000 cases of sepsis are registered annually. In Russia, the frequency of obstetric purulent-inflammatory diseases in the structure of maternal mortality ranges from 5 to 26%, according to some data - up to 45-75%. In the structure of maternal mortality, this pathology is in second or third place. Numerous studies have shown that the use of extracorporeal sorption methods that eliminate endotoxin and cytokines improves the results of treatment of patients with septic shock. The main goal of the study was to obtain new data on the efficacy and safety of using the Efferon LPS device for hemosorption of lipopolysaccharides during extracorporeal detoxification in patients with obstetric sepsis.
Где проходит
7 центров в 6 городахОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT05711901 Официальный реестр (США) · загружено 9 ноября 2026Номер протокола, название, цель, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.